

FOR IMMEDIATE RELEASE

October 21, 2020

CONTACT:

Press@AIR340B.com

NEW REPORT: Contract Pharmacy Participation in 340B Continues to Grow with Little Patient Benefit

WASHINGTON – The Alliance for Integrity and Reform of 340B (AIR340B) released an updated <u>report</u>, "The Impact of Growth in 340B Contract Pharmacy Arrangements – Six Years Later," which highlights the increasing concerns being raised regarding the role contract pharmacies play in the 340B Drug Discount Program.

"Yet another six years have passed – leaving our most vulnerable patients without the benefits they need – and the 340B program remains woefully mishandled. It is long past time for action. Multiple government oversight agencies, health care experts, and researchers, along with AIR340B, have been waving the red flag about the lack of evidence that vulnerable patients are benefiting and the exponential growth in the number of for-profit chain pharmacies participating in the 340B program," said Bob Dold, former Illinois Congressman and AIR340B spokesman. "This new report provides a comprehensive look at the negative impact contract pharmacies are having on the 340B program and highlights the continuing questions regarding whether patients are benefiting as they should from the 340B program. We urge Congress and the administration to fix 340B, so patients are benefiting, and the true intent of this program is achieved."

Read the full report here.

###

The Alliance for Integrity and Reform of 340B (AIR340B) is a coalition of patient advocacy groups, clinical care providers, and biopharmaceutical innovators dedicated to reforming and strengthening the 340B program to ensure it directly supports access to outpatient prescription medicines for uninsured indigent patients. www.340Breform.org